Xgeva® (denosumab): Risk of new primary malignancy

Kadar pengguna: 3 / 5

bintang aktifbintang aktifbintang aktifBintang tidak aktifBintang tidak aktif



New primary malignancies have been reported more frequently in patients treated with Xgeva® (denosumab 120mg once monthly) compared to zoledronic acid (4mg once monthly), according to analysis of four clinical studies in patients with advanced malignancies involving bone.

New primary malignancy occurred in 54/3691 (1.5%) of patients treated with Xgeva® (median exposure of 13.8 months; range: 1.0–51.7) compared to 33/3688 (0.9%) of patients treated with zoledronic acid (median exposure of 12.9 months; range: 1.0–50.8). The cumulative incidence at one year was 1.1% for denosumab and 0.6% for zoledronic acid, respectively. There was no apparent treatment-related pattern in individual cancers or cancer groupings.

A Direct Healthcare Professional Communication (DHPC) letter has been issued by Zuellig Pharma Sdn. Bhd. in agreement with NPRA to highlight this safety issue. Please refer to the DHPC for more information.


National Pharmaceutical Regulatory Agency (NPRA)

Lot 36, Jalan Universiti (Jalan Prof Diraja Ungku Aziz), 46200 Petaling Jaya, Selangor, Malaysia.

  • Phone: +603-7883 5400



Image   Image   Image   Image  


The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Mobile Web :

Site Last Modified

  • Last Modified: Khamis 13 Jun 2024, 10:32:42.
© Copyright 2018 . All Rights Reserved National Pharmaceutical Regulatory Agency NPRA


Menu Utama